-
公开(公告)号：US09783495B2
公开(公告)日：2017-10-10
申请号：US15345035
申请日：2016-11-07
发明人： Bipin Pandey , Kaushik Sata , Himanshu Kothari , Pankaj R. Patel
IPC分类号： C07D207/33
CPC分类号： C07D207/333 , A61K9/2009 , A61K9/2013 , A61K31/40 , A61K45/06 , C07D207/33
摘要： The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
-
公开(公告)号：US09598418B2
公开(公告)日：2017-03-21
申请号：US14647088
申请日：2013-12-23
IPC分类号： C07D498/04 , C07D487/04 , C07D237/32 , C07D491/048 , C07D495/04 , C07D513/04 , C07D403/10
CPC分类号： C07D487/04 , C07D237/32 , C07D403/10 , C07D491/048 , C07D495/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
-
3.发明申请SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 有权取代的苯乙酮-1（2H） - 酮衍生物作为聚（ADP-赖酮）聚合酶-1的选择性抑制剂公开(公告)号：US20150291603A1
公开(公告)日：2015-10-15
申请号：US14647088
申请日：2013-12-13
IPC分类号： C07D487/04 , C07D513/04 , C07D498/04 , C07D491/048 , C07D403/10
CPC分类号： C07D487/04 , C07D237/32 , C07D403/10 , C07D491/048 , C07D495/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
摘要翻译： 本发明涉及通式（I）的新型化合物，其立体异构体，区域异构体，互变异构形式和参与其合成的新中间体，其药学上可接受的盐，药学上可接受的溶剂合物和含有它们的药物组合物。 本发明还涉及制备通式（I）的新化合物，其立体异构体，区域异构体，其互变异构形式，其药学上可接受的盐，药学上可接受的溶剂合物，含有它们的药物组合物以及参与其合成的新型中间体的方法。
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
